Credits Available: 4.25 AMA PRA Category 1 Credits™, 4.25 ANCC Contact Hours, 4.25 ACPE

Description: This dynamic curriculum, detailed by a specialty center clinician, explores each of the CD 19-directed CAR T-cell therapies available for the treatment of DLBCL; solutions to referral and logistic challenges; in-depth early and late toxicity management in CAR T-cell treatment; and the delivery of goal-concordant care using shared decision-making strategies. A challenging real-world case scenario discussion within each Gather-ed group highlights critical decision points, key challenges, and opportunities to incorporate collective insights.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Pharmacist, Physician Assistant, Nurse, Pharmacy Director
Target Specialties: Hematology, Hematology/Oncology, Oncology

Amitkumar Mehta

University of Alabama at Birmingham
Director, Lymphoma and IEC therapy program

I am an Associate Professor and Director of Lymphoma Program at UAB and O’Neal comprehensive Cancer Center at UAB (O’Neal). I am board certified in Internal Medicine, Hematology and Oncology. My focus of interest is LYMPHOMA (Hodgkin lymphoma, Non Hodgkin lymphoma-T cell and B cell lymphomas). I specialize in treatments all types of lymphoma. As a clinical investigator I am also part of many clinical trials as principal investigator or sub investigator in treatment of Lymphoma.

As a Director of Immune Effector Cell Therapy (IEC/CAR-T Program), I have extensive experience in CAR-T treatment in Lymphoma. I also lead the Clinical Trial Office at O'Neal.

My passion is to develop targeted and immunologic therapies in lymphomas with less toxicities and more effectiveness.